Therapeutic Approach

Archive: February, 2017

Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

LOS ANGELES (February 27, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 2016. Recent Highlights Last patient dosing and all […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy

Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy LOS ANGELES (February 13, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it is […]

Leave Your Comments »

Lactose Intolerance: It Means Business

Lactose Intolerance means just what it says…no fancy words, no fluff, just a straight shooter.  If you suffer from lactose intolerance you understand that this condition means business.  But for those of you lucky enough to not be included in the over 1 billion global population* that suffer from this condition, let me break it […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD